Recent news on Mometasone

Advair Not Likely To Be Displaced With Launch Of New Product  -  May 23, 2007
MediaPost Publications,IN THE DRUG TREATMENT MARKET for asthma, the launch of Schering-Plough/Novartis' indacaterol/mometasone is not likely to displace market leader

Launch and Uptake of New Asthma Drug From Schering-Plough/Novartis ...  -  May 21, 2007
PR Newswire (press release),According to the new Pharmacor report entitled Asthma, the launch of the once-daily emerging therapy indacaterol/mometasone-estimated to achieve blockbuster

Launch and Uptake of New Asthma Drug From Schering-Plough/Novartis ...  -  May 21, 2007
PR-Inside.com (Pressemitteilung),...finds that the launch and uptake of Schering-Plough/Novartis's indacaterol/mometasone will not displace market leader GlaxoSmithKline's Advair/Seretide

Schering-Plough announces European approval of new formulations of ...  -  May 1, 2007
News-Medical.net,Additional products from the company's research efforts include the CLARITIN (loratadine) family of nonsedating antihistamines and NASONEX (mometasone

Schering-Plough Announces EU Approval of Two New Formulations of ...  -  Apr 26, 2007
PR-Inside.com (Pressemitteilung),...efforts include the CLARITIN(R) (loratadine) family of nonsedating antihistamines and NASONEX (R) (mometasone furoate monohydrate) Nasal Spray, 50 mcg.

Reader suggests cure for itching ears  -  Apr 16, 2007
Canton Repository (subscription),He said the skin in my ears was infected, and he prescribed drops (Acetic Acid 2 percent Otic Solution USP,) mometasone auroate 0.1 percent, and cream to be

Schering-Plough/Novartis's Upcoming Combination Drug for Asthma ...  -  Mar 28, 2007
Drug Newswire (press release),..."Although indacaterol/mometasone matches Symbicort on all measures of efficacy and safety, indacaterol/mometasone has a superior delivery profile owing to

Steroid Nasal Sprays Relieve Sinusitis Symptoms  -  Apr 24, 2007
eMaxHealth.com,Intranasal corticosteroids used included fluticasone propionate (Flonase), mometasone furoate (Nasonex) and budesonide (Rhinocort).

SP delivers again, beating forecasts  -  Apr 20, 2007
Pharma Times (subscription),Revenues from allergy drugs also gained, with Nasonex (mometasone furoateup) up 24% to $284 million, Claritin (loratadine) up 11% to $112 million and sales

Singapore growing biopharma strength  -  Apr 2, 2007
DrugResearcher.com,...pharmaceutical manufacturing plant, followed up by a $25m investment in facilities for its dry powder inhaler product, Asmanex (mometasone), in 1999.

Steroid-Free Astelin(R) Nasal Spray (R) Demonstrated Seasonal ...  -  25 Feb 2007
PR Newswire (press release),In addition, a group of patients treated with intranasal Nasonex(R) (mometasone furoate monohydrate) did not show symptom improvement compared to placebo

Schering-Plough Cites Today's Anacor Agreement as Latest in Series ...  -  Feb 2, 2007
PR Newswire (press release),Schering-Plough's once daily inhaled corticosteroid mometasone, the active ingredient in ASMANEX (mometasone furoate) and Novartis' once daily beta2-agonist

Schering-Plough's turnaround is moving on apace  -  Jan 30, 2007
Pharma Times (subscription),Sales of the arthritis drug Remicade (infliximab)advanced 34% to $337 million in the quarter, helped by expanded indications, while Nasonex (mometasone

Schering-Plough parades its partnership credentials  -  Feb 5, 2007
Pharma Times (subscription),The inhaled product would combine SP's inhaled steroid Asmanex (mometasone furoate) with a novel beta agonist, indacaterol (QAB149), developed by Novartis.

CombinatoRx Announces Portfolio Advancements  -  Jan 9, 2007
PipelineReview.com (press release),CRx-191 is a selective steroid amplifier containing a mid-potency steroid mometasone and the anti-depressant nortriptyline. CRx-191 works through a novel

Nasonex (Mometasone Furoate Monohydrate) Approved by Health Canada ...  -  Dec 5, 2006
DG NewsPOINTE-CLAIRE, QC, CANADA -- December 6, 2006 -- Schering Canada announced that Nasonex® (mometasone furoate monohydrate) has been approved by Health Canada

International Approvals: Solaraze, Nasonex, Advate  -  Dec 5, 2006
Medscape (subscription)On November 24, Health Canada approved a new indication for mometasone furoate monohydrate nasal spray (Nasonex, made by Schering Canada, Inc), allowing its

New Data Show Incidence of Drowsiness and Sedation is Higher for ...  -  Nov 30, 2006
Drug Newswire (press release),Additional products from the company's research efforts include the CLARITIN(R) (loratadine) family of nonsedating antihistamines and NASONEX(R) (mometasone

New Data Show Incidence of Drowsiness and Sedation is Higher for ...  -  Nov 30, 2006
Earthtimes.orgAdditional products from the company's research effortsinclude the CLARITIN(R) (loratadine) family of nonsedating antihistamines andNASONEX(R) (mometasone

Novartis Highlights Strong R&D Pipeline, Plans For Multiple New ...  -  Nov 29, 2006
Medical News Today (press release),The QMF149 program, which combines QAB149 with the once-daily inhaled corticosteroid mometasone (Asmanex®)[3], is set to begin trials in 2007 with plans for

Scent-Free Nasonex(R) (Mometasone Furoate Monohydrate) Now ...  Oct 20, 2006
POINTE-CLAIRE, QUEBEC, CANADA -- October 20, 2006 -- Nasonex® (mometasone furoate monohydrate), the number one doctor-prescribed nasal spray in Canada for the ... -DG News Asthma/COPD Combination Products Here to Stay  Oct 11, 2006
SkyePharma/Kos Pharmaceuticals' fluticasone/formoterol and Schering-Plough/Novartis' mometasone/formoterol are ICS/LABA combinations currently in development. ... -International News Service, Schering-Plough Reports Financial Results for 2006 Third Quarter  Oct 20, 2006
Schering-Plough's once-daily inhaled corticosteroid mometasone (the active ingredient in ASMANEX) and Novartis' once-daily beta2- agonist indacaterol (QAB149 ... -PR Newswire (press release), Novartis Delivers Dynamic Sales and Earnings Growth in the First ...  Oct 18, 2006
The goal is to combine the beta-agonist QAB149 (indacaterol) of Novartis with Schering-Plough's corticosteroid mometasone (Asmanex®) in a single inhalation ... -Market Wire (press release) Novartis and Schering-Plough collaborate on once-daily combination ...  Sep 7, 2006
...the once daily long and fast acting Beta2-agonist QAB149 (indacaterol) of Novartis and Schering-Plough's once-daily oral corticosteroid mometasone (Asmanex) in ... -Therapeutics Daily (subscription)

Nasonex (Mometasone Furoate Monohydrate) Approved by Health Canada ...  -  Dec 5, 2006
DG NewsPOINTE-CLAIRE, QC, CANADA -- December 6, 2006 -- Schering Canada announced that Nasonex® (mometasone furoate monohydrate) has been approved by Health Canada

Mometasone Equivalent to Fluticasone in Patients with Moderate to ...  -  Nov 15, 2006
DG NewsBesides confirming the efficacy of the mometasone treatment, the study may reflect a renewed interest in single-agent approaches to controlling asthma,

International Approvals: Solaraze, Nasonex, Advate  -  Dec 5, 2006
Medscape (subscription)On November 24, Health Canada approved a new indication for mometasone furoate monohydrate nasal spray (Nasonex, made by Schering Canada, Inc), allowing its

New Data Show Incidence of Drowsiness and Sedation is Higher for ...  -  Nov 30, 2006
Drug Newswire (press release),Additional products from the company's research efforts include the CLARITIN(R) (loratadine) family of nonsedating antihistamines and NASONEX(R) (mometasone

New Data Show Incidence of Drowsiness and Sedation is Higher for ...  -  Nov 30, 2006
Earthtimes.orgAdditional products from the company's research effortsinclude the CLARITIN(R) (loratadine) family of nonsedating antihistamines andNASONEX(R) (mometasone

Novartis Highlights Strong R&D Pipeline, Plans For Multiple New ...  -  Nov 29, 2006
Medical News Today (press release),The QMF149 program, which combines QAB149 with the once-daily inhaled corticosteroid mometasone (Asmanex®)[3], is set to begin trials in 2007 with plans for

Novartis And Schering-Plough Collaboration To Develop Novel Once ...  Aug 20, 2006
...once daily long and fast acting Beta2-agonist QAB149 (indacaterol) of Novartis and Schering-Plough's once-daily oral corticosteroid mometasone (Asmanex®) in a ... -Medical News Today

Schering-Plough Announces Global Agreement With Novartis to ...  Aug 13, 2006
Schering-Plough's once daily inhaled corticosteroid mometasone, the active ingredient in ASMANEX(R) and Novartis' once daily beta2-agonist indacaterol (QAB149 ... -Finanzen.net

Novartis, Schering-Plough in respiratory therapy  Aug 13, 2006
...the once daily long and fast acting Beta2-agonist QAB149, indacaterol, of Novartis and Schering-Plough's once-daily oral corticosteroid mometasone Asmanex in a ... -MarketWatch

Schering-Plough and Novartis Announce Joint Venture  Aug 14, 2006
Schering-Plough's inhaled corticosteroid mometasone and Switzerland-based Novartis' beta 2 agonist, indacaterol, will be combined in a single inhalation device ... -Business New Jersey (subscription)

Schering-Plough, Novartis in joint venture  Aug 14, 2006
Schering-Plough`s fixed-dose corticosteroid mometasone, the active ingredient in Asmanex, and Novartis` once-daily beta2-agonist indacaterol will be combined ... -Monsters and Critics.com

UPDATE 2-Novartis, Schering-Plough in asthma dual-drug deal  Aug 14, 2006
Novartis said the once-daily inhaled fixed-dose combination product would pair Schering-Plough's inhaled corticosteroid Asmanex (mometasone) with Novartis ... -Reuters

UPI NewsTrack Business August 14, 2006  Aug 14, 2006
Schering-Plough's fixed-dose corticosteroid mometasone, the active ingredient in Asmanex, and Novartis' once-daily beta2-agonist indacaterol will be combined ... -Political Gateway

Schering Plough, Novartis join hands for combination therapy  Aug 14, 2006
...of Novartis’ once daily long and fast acting Beta2-agonist QAB149, indacaterol, and Schering-Plough's once-daily oral corticosteroid mometasone Asmanex in a ... -newratings.com

Novartis, Schering-Plough link up for once-daily asthma combo  Aug 14, 2006
The inhaled product would combine Schering-Plough's inhaled steroid Asmanex (mometasone furoate) with a novel beta agonist, indacaterol (QAB149), developed by ... -Pharma Times (subscription)

Schering-Plough Announces Global Agreement with Novartis and ...  Aug 15, 2006
Schering-Plough's once daily inhaled corticosteroid mometasone, the active ingredient in ASMANEX® and Novartis' once daily beta2-agonist indacaterol (QAB149 ... -Financial News USA

SP and Novartis develop asthma/COPD drug  Aug 14, 2006
The firm added that the new product would combine its once-daily inhaled corticosteroid mometasone, the active ingredient in Asmanex, with Novartis ... -Therapeutics Daily (subscription)

AstraZeneca's Symbicort the first of many new combination drugs to ...  Jul 27, 2006
ICS/LABA combinations in development include SkyePharma/Kos Pharmaceuticals' fluticasone/formoterol and Schering-Plough/Novartis' mometasone/formoterol, which ... -Pharmaceutical Business Review

SCHERING-PLOUGH APPOINTS HERB EHRENTHAL GROUP VICE PRESIDENT ...  Jul 11, 2006
Under his leadership, he and his team have received awards for the VYTORIN and NASONEX® (mometasone furoate monohydrate) ad campaigns. ... -Business New Jersey (subscription)

Schering-Plough to Expand Its Presence in Latin America ...  Jun 21, 2006
ZETIA(R) (ezetimibe), ZETSIM(R) (ezetimibe/simvastatin), CLARITIN(R) (loratadine), CLARINEX(R) (desloratadine) and NASONEX(R) (mometasone furoate monohydrate). ... -Finanzen.net



Your Health This Month  May 2, 2006
...better than the antibiotic. The particular nasal spray chosen for this study was the steroid mometasone. Its manufacturer was a ... - Slate

Springtime allergies: Solutions for a problem in full bloom  May 5, 2006
...symptoms. Examples include fluticasone propionate (Flonase), budesonide (Rhinocort), mometasone (Nasonex) and triamcinolone (Nasacort). ... - MayoClinic.com

Are You Allergic to Your Town?  Apr 18, 2006
...& Gamble, makers of Febreze Allergen Reducer(R) Fabric Refresher and Swiffer(R) Dusters, Schering-Plough, makers of Nasonex(R) (mometasone furoate monohydrate ... - PR Newswire





Taro Receives Final Approval for Mometasone Furoate Topical ...  Mar 15, 2006
...has received final approval from the US Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Mometasone Furoate Topical ... - Genetic Engineering News

Taro Pharma Gets Final FDA Approval For Mometasone Furoate Topical ...  Mar 15, 2006
US affiliate, Taro Pharmaceuticals USA Inc., has received final approval from the FDA for its Abbreviated New Drug Application for Mometasone Furoate Topical ... - Trading Markets

Taro Pharma's ANDA For Mometasone Furoate Lotion Gets Final FDA ...  Mar 15, 2006
...received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application or ANDA for Mometasone Furoate Topical Solution USP ... - Trading Markets

FDA approves Taro skin treatment  Mar 16, 2006
The company received final approval for the marketing of its lotion Mometasone, which will have annual US sales of $9.6 million. ... - Globes

Health: Something To Sneeze At  Mar 22, 2006
...effective than antihistamines. Popular brands include Flonase (fluticasone propionate) and Nasonex (mometasone), among others. The drugs ... - Standard-Speaker

Taro OK'd for generic of Schering topical  Mar 15, 2006
The company said the Food and Drug Administration has given approval to its mometasone furoate topical solution, 0.1 percent lotion for the temporary relief of ... - United Press International



Schering-Plough swings to profit in Q4  Jan 31, 2006
Japan; the Crohn's disease and arthritis drug Remicade (infliximab), which jumped 19% to $251 million; the allergy drug Nasonex (mometasone furoate monohydrate ... - Pharma Times (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional